Epsilogen

Epsilogen Overview

Founded 2016
Founded
Status Private
Latest Deal Type Early Stage VC
Latest Deal Amount $3.75M
Latest Deal Amount
Investors 5

Epsilogen General Information

Description

Developer of an immuno-oncology company intended to develop immunoglobulin antibodies to treat cancer. The company's offerings include IgE-based drugs targeting solid tumors, enabling patients to kill parasites that reside in human tissue, also the home of the solid tumor.

Contact Information

Formerly Known As
IGEM Therapeutics Ltd, IGEM, IGEM Therapeutics Limited, IGEM Therapeutics
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Primary Office
  • London BioScience Innovation
  • Centre, 2 Royal College Street
  • London NW1 0NH
  • England, United Kingdom
+44 020 0000 0000

Epsilogen Timeline

2017201820192020
Date FoundedFinancing Round
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Epsilogen Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Early Stage VC 20-Apr-2020 $3.75M 000.00 000.00 Completed Clinical Trials - Phase 1
3. Grant 02-Apr-2019 00000 00.000 Completed Clinical Trials - Phase 1
2. Early Stage VC (Series A) 30-Nov-2018 $6.45M $6.45M 000 Completed Clinical Trials - Phase 1
1. Grant 09-May-2018 $2.02M Completed Clinical Trials - Phase 1

Epsilogen Cap Table

To view Epsilogen‘s complete cap table, request access »
Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A2 0,000,000 00.000000 00.00 00.00 00 00.00 00.000
Series A 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.00

Epsilogen Executive Team (5)

Name Title Board Seat Contact Info
Tim Wilson Ph.D Chief Executive Officer & Board Member
Kevin FitzGerald Ph.D Chief Scientific Officer
Vivienne Cox Ph.D Director of Research Operations & Board Member
Ian Ardill Chief Financial Officer
David Chiswell Ph.D Chairman

Epsilogen Board Members (6)

To view Epsilogen‘s full board member team, request access »
Name Representing Role Since
Alek Safarian ALSA Ventures Board Member 000 0000
David Chiswell Ph.D Self Chairman 000 0000
Peter Finan Ph.D Epidarex Capital Board Member 000 0000
Robert Balfour Ph.D ALSA Ventures Board Member 000 0000
Tim Wilson Ph.D Epsilogen Chief Executive Officer & Board Member 000 0000

Epsilogen Investors (5)

To view Epsilogen‘s full investor history, request access »
Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
AlbionVC Corporate Venture Capital Minority 000 0000 000000 0
ALSA Ventures Venture Capital Minority 000 0000 000000 0
Epidarex Capital Venture Capital Minority 000 0000 000000 0
University College London University Minority 000 0000 000000 0
Innovate UK Government Minority 000 0000 000000 0

Ready to get started?

Request a free trial